tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
CervoMed upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe FlyCervoMed upgraded to Buy from Neutral at H.C. Wainwright
12d ago
CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
Premium
Ratings
CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
13d ago
CervoMed announces FDA alignment on neflamapimod registration path
Premium
The Fly
CervoMed announces FDA alignment on neflamapimod registration path
13d ago
Cervomed Inc.’s Promising Phase 2a Study on Neflamapimod for Aphasia
PremiumCompany AnnouncementsCervomed Inc.’s Promising Phase 2a Study on Neflamapimod for Aphasia
20d ago
CervoMed Releases Investor Presentation on Website
Premium
Company Announcements
CervoMed Releases Investor Presentation on Website
25d ago
CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating
Premium
Ratings
CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating
1M ago
CervoMed appoints Matthew Winton as chief commercial, business officer
PremiumThe FlyCervoMed appoints Matthew Winton as chief commercial, business officer
1M ago
CervoMed announces development program, benefits of neflamapimod
Premium
The Fly
CervoMed announces development program, benefits of neflamapimod
2M ago
H.C. Wainwright sets CervoMed price target into FDA clarity
Premium
The Fly
H.C. Wainwright sets CervoMed price target into FDA clarity
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100